Pfizer has said repeatedly since June that it was targeting October for its application and the companies started a large late-stage study last month of the candidate vaccine, one of the few globally in later stages of development. On Thursday they reported data from previous early-stage trials of the vaccine, BNT162b2, that showed it induced similar immune responses and had milder side effects than prior data on another candidate. Pfizer stock, down 1% this year, has trailed the stellar rises in value of major pharmaceutical companies this year.
Post Top Ad
Your Ad Spot
Friday, August 21, 2020
Pfizer, BioNTech shares gain as more data backs vaccine candidate
Tags
Yahoo Finance#
Share This
About Business World
Yahoo Finance
Labels:
Yahoo Finance
Subscribe to:
Post Comments (Atom)
Sponsor
Ad Banner
Your Ad Spot
Author Details
Rathore Post covers What’s happening in the world. News, Politics, Business, Entertainment, Sports, Latest Technology about software, mobile ,computer science, internet, semiconductor, telecom and science, Latest Modern Fashion news, Modern Beauty Information, Health Disease Information & Home treatment Remedies & Affiliate marketing program in all of our journalism.
No comments:
Post a Comment